Acute kidney injury (AKI) is characterized by abrupt deterioration of renal function, and its diagnosis relies on creatinine measurements and urine output. AKI is associated with higher morbidity and mortality, and is a risk factor for development of chronic kidney disease. There is no proven medication for AKI. Therefore, prevention and early detection are important. Physicians should be aware of the risk factors for AKI and should monitor renal function in high-risk patients. Management of AKI includes optimization of volume status and renal perfusion, avoidance of nephrotoxic agents, and sufficient nutritional support. Continuous renal replacement therapy is widely available for critically ill children, and this review provides basic information regarding this therapy. Long-term follow-up of patients with AKI for renal function, blood pressure, and proteinuria is recommended.
Introduction
Acute kidney injury (AKI), previously known as acute renal failure, indicates abrupt deterio ration of renal function. While acute renal failure often implies anuria and urgent need of emergency renal replacement therapy (RRT), AKI is a broader term coined to detect this condi tion at an early stage, thereby improving its outcome through early intervention. AKI occurs in about 60% of patients in the intensive care unit (ICU). In fact, even earlystage AKI is proven to be associated with higher morbidity and mortality ( Fig. 1) , 1) especially in critically ill patients.
In addition, there is mounting evidence against the previous notion that no longterm sequelae can occur after complete resolution of acute renal failure; AKI is a risk factor for chronic kidney disease (CKD). 1) Therefore, timely detection of and intervention for AKI are necessary to improve the shortterm outcome of this condition and to prevent CKD.
Definition of AKI
Authors of various studies previously used their own definitions of AKI, which have hindered appropriate collective studies on AKI. In 2012, Kidney Disease: Improving Global Outcomes (KDIGO) announced a new definition of AKI, summarizing the previously widely accepted criteria (Table 1) . 2) For neonates, modification of criteria of absolute creatinine level for stage III AKI was proposed as 2.5 mg/dL. 3) However, the definition of AKI based on serum creatinine level has several limitations. Serum creatinine is a functional marker of the kidney; its level increases hours or days after renal injury. Creatinine is dependent on muscle mass; fluid overload might dilute the serum creatinine concentration, and its clearance may be altered with the drug cimetidine or other organic molecules, as well as in systemic diseases. Notably, cystatin C, an inhibitor of cysteine proteinases from all nucleated cells, 4) irrespective of mus cle mass and age, is considered as an alternative for creatinine in estimating renal clearance. Glomerular filtration rate estimation equation using cystatin C was more accurate than that using crea tinine. 5) However, cystatin C is affected by diabetes, highdose corti costeroids, hyperthyroidism, inflammation, hyperbilirubinemia, rheumatoid factor, and hypertriglyceridemia. 6) Biomarkers of kidney injury, namely tubular injury markers of NacetylβDglucosaminidase (proximal tubular damage marker), neutrophil gelatinaseassociated lipocalin (approved in Korea and other countries), kidney injury molecule1, liver fatty acidbinding protein (approved in Japan), and kidney stress and cell cycle arrest marker TIMP2 & IGFBP7 (NephroCheck [Astute Medical, San Diego, CA, USA], approved in USA), 7, 8) have been investigated and validated. However, these are not yet widely used in clinics.
9)

Causes of AKI
Once AKI is detected, a physician should determine its causes and manage them accordingly. Dehydration or decreased renal perfusion is the most common cause of AKI, followed by drug or nephrotoxin induced AKI. 10, 11) Glomerulopathies including hemolytic uremic syndrome and all kinds of glomerulonephritis often accompany AKI (Table 2) . 6, 12, 13) A type of infectioninduced acute tubulointerstitial disease is noteworthy. When a child presents with prolonged fever of unknown origin followed by gastrointestinal symptoms of abdominal pain and diarrhea, leading to a diagnosis of AKI, Yersinia pseudotuberculosis 
Stage
Serum creatinine Urine output 1 1.5 to 1.9 times baseline or ≥0.3 mg/dL (≥26.5 μmol/L) increase <0.5 mL/kg/hr for 6 to 12 hr 2 2.0 to 2.9 times baseline <0.5 mL/kg/hour for ≥12 hr 3 3.0 times baseline or increase in serum creatinine to ≥4.0 mg/dL (≥353.6 μmol/L) or initiation of renal replacement therapy or in patients <18 years a decrease in eGFR to <35 mL/minute per 1.73 m 2 <0.3 mL/kg/hr for ≥24 hours or anuria for ≥12 hr Table 2 . Korean J Pediatr 2018;61 (11) :339-347 infection should be considered. 14) Y. pseudotuberculosis infection is spread by consumption of unsanitized water, and it may be com plicated by AKI, which is selflimiting. It often resembles Kawasaki like disease, with strawberry tongue, desquamation of the fingertips, and dilatation of coronary arteries (Fig. 2 ).
14)
How to manage AKI
There is no proven medication for AKI. Therefore, prevention and early detection is the mainstay of management of AKI.
Identification of at-risk patients, monitoring, and early detection
In general, dehydration; advanced age or prematurity; chronic diseases, especially CKD, diabetes, hypertension, cancer, anemia, and proteinuria in adults render the host susceptible to AKI 15) ; volume depletion, sepsis, critical illness, cardiopulmonary bypass, ICU care, extracorporeal membrane oxygenation, surgery, ventilation, vasopressor usage, and exposure to nephrotoxins lead to an in creased risk of AKI (Table 3) . 2, 16) Every condition associated with AKI has its own risk factors; therefore, physicians should be aware of these risk factors for their disease of interest and should carefully monitor renal function in patients at risk of AKI. 10) For example, pediatric cardiac surgery; cyanotic heart disease; long extracorporeal circulation; higher risk according to the RACHS1 (riskadjusted classification for con genital heart surgery); postoperative low cardiac output syndrome; pump failure; sepsis; hematologic complications; preoperative dependency on the ventilator; treatment with milrinone, gentamicin, or furosemide; duration of anesthesia; use of multiple crossclamps;
and transfusion have been reported as risk factors for AKI. 17, 18) A kidney scoring system called renal angina index was proposed to predict AKI in critically ill children. 16) It predicted AKI on the basis of subtle kidney injury (change of estimated creatinine clearance, or fluid overload) and patient risk factors (ICU admission, stem cell transplantation, ventilation and inotropy).
16)
Optimization of volume status and circulation: avoid hypovolemia and fluid overload
Adequate renal perfusion is essential to prevent AKI and to re cover from it. Optimal blood pressure and intravascular volume of the patient should be maintained (mean arterial pressure>65 mmHg or higher for a previously hypertensive host, central venous pressure 8-12 mmHg for an adult). Fluid resuscitation is initially necessary for patients with hypotension, if the hypotension is partially due to hypovolemia; however, fluid overload (weight gain more than 10%) 14) WBC, white blood cell; ESR, erythrocyte sedimen tation rate. With regard to the choice of resuscitation fluid, studies have shown that patients treated with colloid solutions such as hydroxye thyl starches show poorer outcomes compared to outcomes in patients treated with normal saline. Albumin seems not inferior to saline, except in patients with traumatic brain injury. 6, 25) Some studies reported that normal saline leads to poorer outcomes than those observed using a balanced salt solution such as Ringers lactate solution. As normal saline is hyperchloremic, it could induce hyperchloremic metabolic acidosis, leading to decreased renal corti cal tissue perfusion. 26) However, recent prospective studies failed to prove the efficacy of balanced solution over that of normal saline.
27,28)
Avoid nephrotoxic agents
Antibiotics such as aminoglycoside, vancomycin (especially when used along with piperacillin/tazobactam), 6) amphotericin, nonsteroidal antiinflammatory drugs (NSAIDs), angiotensinogen converting enzyme inhibitor, angiotensin receptor blocker, calcine urin inhibitors, and chemotherapeutic agents such as cispla tin and methotrexate are wellknown nephrotoxins. These nephrotoxins should be avoided in patients at risk of AKI and in those with esta blished AKI. If the use of these agents is unavoidable, their dosage or dosing interval should be adjusted to reduce renal toxicity. For example, a once daily dose of aminoglycoside is less nephrotoxic than other regimens. In addition, the trough level should be mea sured and adjusted accordingly. 29) Contrast media used for angiography and computed tomography is nephrotoxic as well. Patients with CKD, diabetes, insufficient circulating blood volume, and those who take NSAIDs are at risk of contrastinduced AKI. Contrast dosage, type, and multiple proce dures increase the risk of this condition. Minimization of contrast media volume, use of lowosmolar and isoosmolar contrast media, and administration of noniodinated contrast media are recommen ded to prevent contrastinduced AKI. 30) Preventive measures in clude intravenous administration of an isotonic normal saline or Hartmann solution at 1 mL/kg/hr 12 hours before and after the procedure, or 3 mL/kg/hr 1 hour before and 6-9 mL/kg over 4-6 hours after the procedure. 6, 30) KDIGO guidelines suggest using Nacetylcysteine in patients at increased risk of contrastinduced AKI, 30) while a recent randomized controlled trial failed to show any benefit of Nacetylcysteine. 31) In addition, nephrotoxins should be discontinued more than 24 hours before the procedure.
4. Nutritional support 6, 32) As AKI is a catabolic status, nutritional support is necessary; oral nutrition is preferred.
Plasma glucose 110-149 mg/dL (caution should be exercised, as patients with AKI are at risk of hypoglycemia)
Total energy intake of 20-30 kcal/kg/day in patients at any stage of AKI (no restriction!) Protein 0.8-1.0 (1.5) g/kg/day in AKI (no RRT), 1.0-1.5 (3-4) g/ kg/day on RRT, up to 1.7 g/kg/day on continuous RRT (CRRT)
Pharmacological intervention
Diuretics are effective only for preventing/ameliorating fluid overload and not for maintaining urine output volume to avoid AKI. Diuretics are not recommended to prevent AKI or to treat established AKI. 33) Mannitol, dopamine (other than as an inotropic), 34) gluco corticoid, 35) fenoldopam, 36) and Nacetylcysteine 37, 38) (other than contrastinduced AKI) are also not recommended.
RRT for severe AKI
When to start
RRT is indicated when metabolic derangement of AKI, such as hyperkalemia or acidosis, and/or fluid overload cannot be managed with medications, or for detoxification. Some researchers recom mend early initiation of RRT, but available data show mixed results in this regard. 39, 40) Fluid overload of more than 10% of the body weight and inability to maintain input-output balance owing to large amount of fluid to treat the patients and/or oliguria are the common indications for RRT.
41)
Which modality to use
Intermittent hemodialysis (IHD), CRRT, and peritoneal dialysis (PD) are available as RRT for AKI. The choice of modality depends on availability at the center and the condition of the patient. IHD is possible only when the patient is hemodynamically stable, and when HD machine appropriate for the size of the patient, and dedi cated personnel (pediatric nephrologist and dialysis nurses capable of performing pediatric IHD) are available. CRRT is a lowdose longduration RRT; therefore, patients who are hemodynamically less stable can be managed with CRRT, usually in the ICU setting. However, it still requires appropriate machines suitable for CRRT in children. Although PD can be applied irrespective of the patient size, its dosage in critically ill patients is highly unpredictable, because dialysis is dependent on the peritoneal circulation. In addition, the risk of catheterrelated infections is higher with PD, with a high risk of peritoneal fluid leakage through the PD catheter insertion site.
Recently, CRRT has become widely available for critically ill patients. Therefore, the following sections will focus on CRRT. In fact, several studies have shown that CRRT is superior to IHD for re covery from AKI, as interdialytic hypotension is more common in IHD than in CRRT.
Vascular access for CRRT
In children, adequacy of CRRT (and IHD) often depends on the adequacy of vascular access, which determines maximum blood flow rate (BFR) and filter lifespan.
41) The shortest and largest possible catheter for the patient are recommended for successful CRRT, which ensures lower resistance and better blood flow (Table 4 
Prescription of CRRT
1) Choice of filter/membrane for CRRT
Once vascular access for dialysis is secured, the CRRT kit to be used should be determined based on patient weight. A filter/mem brane with a surface area closest to the body surface area (BSA) of the patient should be chosen (Table 5 ). The extracorporeal blood volume necessary to use the respective circuit should be known; allowable extracorporeal volume is less than 8 mL/kg (<10%-20% of the plasma volume). The difference between required circuit volume and allowable extracorporeal volume can be filled by priming the circuit with blood (blood priming) or 5% albumin.
2) Choice of CRRT mode (Ultra)filtration (hemofiltration, HF) uses convection to remove fluid and its solute across the membrane by a transmembrane (hydrostatic) pressure gradient that is exerted by the pump of the CRRT machine; the removed fluid is replaced by adding "replacement fluid" through the prefilter or postfilter port of the CRRT circuit. Hemodialysis (HD) uses diffusion of solute between blood (plasma) and dialysate (flowing in a direction opposite to that of the plasma to maximize the solute concentration difference) through filter (mem brane) by the concentration difference. Convection can remove larger molecules than diffusion does; therefore, if the target mole cule is large, HF is the preferred mode of CRRT. With continuous venovenous hemodiafiltration (CVVHDF), HD and HF are applied simultaneously; their ratio can be decided according to the condition of the patient. If the target molecule is small, such as that of ammonia, the ratio of HD can be increased for faster removal of the molecule.
3) Choice of CRRT fluid
Patients who require CRRT often have severe AKI with hyper phosphatemia and hyperkalemia. Therefore, the components of CRRT fluid are designed to treat these metabolic derangements (Table 6 ). In case of normal phosphorous/potassium levels, the CRRT fluid of the patient needs to be supplemented with additional phosphorous/potassium. Commercialized CRRT fluids containing additional phosphorous/potassium are available.
4) Intensity of RRT
Creatinine clearance by CRRT is assumed to be equal to the efflu ent rate, as the creatinine concentration of the effluent from dialysis is equal to the serum creatinine (as long as the dialysis membrane is functional, because BFR is much higher than the countercurrent dialysate flow rate [DFR]), and that of the effluent of ultrafiltration is equal to that of plasma (excluding large molecules that cannot pass the filtration). Although the optimal intensity of RRT is debatable, a filtration rate of 20- ) is considered sufficiently high 42, 43) ; in this way, effluent volume is calculated. Then, the effluent rate is ideally equal to the sum of the DFR and replacement fluid flow rate (RFFR), the ratio of which is set by the physician. When HD:HF= 1:1, DFR and RFFR can be set as 10-17.5 mL/hr/kg. In practice, the delivered CRRT may not be equal to the prescribed dose; therefore, prescription should be 120%-125% of the computed clearance. 41) When higher clearance is required, such as in hyperammonemia, DFR can be set to more than 2,100 mL/hr/1.73 m 2 .
Calculation of BFR
A minimum BFR of 30-50 mL/min is necessary for CRRT; the BFR should be up to 400 mL/min/BSA 1.73 m 2 (250 mL/min), or 10-12 mL/kg/min for neonates and infants (weight<5 kg), 5-10 mL/ kg/min in children (weight<30 kg), and 2-5 mL/kg/min for older children (weight≥30 kg). BFR is supposed to be 5-10 fold higher than DFR or RFFR. Ultrafiltrate (removed fluid from the plasma) should be less than 20% of the plasma; therefore, plasma flow rate (BFR×[1hematocrit]) should be more than 5 times the ultrafiltration rate. Ultrafiltration rate is the sum of RFFR (which is removed as convection) and patient removal rate (PRR, [total input−total output +desired fluid removal]/24). Therefore, BFR should be larger than (5×[RFFR+PRR]/60 min)/(1−hematocrit).
Anticoagulation
Anticoagulation is necessary to maintain extracorporeal circula tion. Systemic anticoagulation with heparin (100 units/mL solution, 10-25 units/kg as loading and 5-10 units/kg/hr as maintenance) is most commonly performed; however, bleedingrelated complications are common, and heparininduced thrombocytopenia is also a concern. Nafamostat mesylate (Futhan [SK chemicals, Seoul, Korea], 0.1-1 mg/kg/hr) is a shortacting (halflife, 5-8 minutes) agent asso ciated with fewer bleedingrelated complications than heparin is. However, regardless of whether heparin or nafamostat mesylate is used, activated clotting time should be monitored regularly. Anti coagulationfree, intermittent saline flushing can be performed for patients with a higher risk of bleeding.
When to end CRRT
When urine output recovers to >400 mL/day in adults and renal creatinine clearance recovers to >20-35 mL/min/1.73 m 2 , CRRT can be discontinued. Korean J Pediatr 2018;61(11):339-347
(phosphorous, potassium, magnesium, pH q 6-8 hours), and effluent volume frequently (9) Consider removal of nutrients and medication via CRRT
Prognosis of AKI: AKI to CKD transition
AKI may cause permanent damage to the kidney by reducing the renal mass, causing renal medullary injury that is highly sensitive to ischemic injury during AKI, and following maladaptive repair and tubular atrophy. 45, 46) A metaanalysis showed that adult patients with AKI have more than 8.8 fold higher risk of CKD and more than 3 fold higher risk for ESRD. 46, 47) KDIGO guidelines recommend that patients with AKI should be followed up at 3 months after recovery from AKI, for renal function, blood pressure, and proteinuria. 29) As the increased risk of CKD years after AKI episodes is well known (Fig.  3) , 4752) longterm followup of such patients is necessary. In addi tion, patients should be educated to avoid exposure to nephro toxins such as NSAIDs and radiocontrast agents, and to actively undergo treatment for diabetes, hypertension, and proteinuria, if present.
Potential interventions of AKI
Through understanding the pathophysiology of AKI, potential therapeutic interventions, such as antiinflammatory agents includ ing recombinant alkaline phosphate, 53) costimulatory molecule CD28 receptor antagonist, 54) antioxidants, vasodilatorcalcium sen si tizer levosimendan, 55) apoptosis inhibitors (p53 siRNA) and repair agents including bone morphogenetic protein7 receptor agonist hepatocyte growth factor, and mesenchymal stem cells, are now under consideration.
53)
Conclusion
AKI is common in critically ill children and is associated with a very poor outcome. As there is no proven effective pharmacological inter vention for AKI, prevention and early detection are important. To prevent and recover from AKI, optimization of volume status and circulation, avoidance of nephrotoxic agents, and sufficient nu tri tional support are necessary. CRRT continues to be increasingly performed for treating severe AKI. Novel biomarkers and potential therapeutic interventions for AKI are being investigated.
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